康方生物新型PD-1/CTLA-4双特异性抗体cadonilimab(AK104)获国家药监局批准,开展一项全球性Ⅲ期临床,以评估cadonilimab加含铂化疗联合/不联合贝伐珠单抗,用于一线治疗持续、复发或转移性宫颈癌的有效性和安全性。去年8月,FDA已授予cadonilimab用于治疗经治、复发或转移性宫颈鳞癌的快速通道资格;cadonilimab用于相同适...
http://www.adverum.com 公司地址:100 Cardinal Way Redwood City California 94063 公司电话:1-650-6569323 今开:3.79昨收:3.94 最高:4.01最低:3.76 涨停价:跌停价: 总市值:80297507 Adverum的热门讨论 持股变动声明 Adverum(ADVM)02-28 05:15 $Adverum(ADVM)$4 Statement of changes in beneficial ownership...
ADVM-022. The candidate is being developed for treating wet age-related macular degeneration ("AMD"). Adverum is in the process of filing a pre-investigational new drug (IND), following its meeting with the FDA in the first quarter of 2017. The company is also...